Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
7440-69-9
Molecular formula
Bi
Molecular weight
208.9804 g/mol
Drug class
Inorganic heavy-metal active moietygastrointestinal mucosal protectant and antimicrobial component of bismuth salts
Mechanism of action
Bismuth compounds exert local gastrointestinal effects through mucosal coating and binding to bacterial proteins and toxins. Certain bismuth salts also have antimicrobial activity against Helicobacter pylori and other enteric organisms; the exact mechanism and use depend on the specific salt and formulation.
Indications / reported uses
Symptomatic relief of diarrhoea and dyspepsia with authorised bismuth subsalicylate products
Component of specific combination regimens for Helicobacter pylori eradication, such as bismuth quadruple therapy; do not assign these indications to all bismuth compounds or formulations
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Bismuth Environmental Risk Assessment (ERA) (the Bismuth ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.